Clinical trials: COVID
COVID-19
Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above
This is a randomized, blinded, positive-controlled study to evaluate the immunogenicity and safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, in population aged 18 years old and above（negative antibody against…
- Trial name
- NCT05663086
- Testing
- One dose group, Two doses group, Aged 18-59 years
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
COVID-19
Study of COVID-19 DNA Vaccine (AG0301-COVID19)
This study will assess the safety and immunogenicity of AG0301-COVID19 in healthy adult volunteers.
- Trial name
- NCT04463472
- Testing
- AG0301-COVID19
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AnGes, Inc.
COVID-19 Pneumonia
Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes
To evaluate the post-marketing immunogenicity and safety of the inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (Vero cells) in patients aged 60 years or older with hypertension and/or diabetes…
- Trial name
- NCT05065892
- Testing
- COVAX
- Where
- 3 sites in China
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
COVID-19, SARS-CoV-2
Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19
The purpose of this study is to to evaluate the safety and immune response of COVI-VAC given as a single booster dose in healthy adults previously vaccinated against COVID-19 with an authorised mRNA or adenovirus-vectored…
- Trial name
- NCT05233826
- Testing
- COVI-VAC
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Codagenix, Inc
COVID-19
Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines
This study is a large-scale investigation (Phase 3) into a new booster shot designed specifically for teenagers. The booster targets a particular variant of COVID-19, Omicron XBB.1.5.
- Trial name
- COVID-19 (NCT05973006)
- Testing
- NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
- Where
- 20 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Novavax
Coronavirus Infection, Severe Acute Respiratory Syndrome
COVID-19 Seroprevalence Study in French Guiana
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.
- Conditions
- Coronavirus Infection, Severe Acute Respiratory Syndrome, SARS-CoV Infection, Covid19
- Trial name
- EPI-COVID-POP (NCT04490850)
- Testing
- Blood sample
- Where
- 5 sites in French Guiana
- Volunteers
- 3,541 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4
Subjects will be recruited and divided into 3 groups: Experimental Group (468 subjects): 1st dose : combined vaccination of COVAX+PPV23, 2nd dose: combined vaccination of COVAX+IIV4; Control Group A (468 subjects): 1st dose…
- Conditions
- Influenza, Human, Pneumonia, Pneumococcal, COVID-19 Pneumonia
- Trial name
- NCT05079152
- Testing
- COVAX+PPV23;COVAX+IIV4, COVAX only (1st and 2nd dose), PPV23 for the 1st dose and IIV4 for the 2nd dose
- Where
- 3 sites in China
- Volunteers
- 1,404 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Corona Virus Infection
BBV152/BBV154 Heterologus Prime-Boost Study
All participants will be assessed for immunogenicity and safety endpoints and provide a blood sample before the administration of the first dose of IP.
- Trial name
- BBV152BBV154 (NCT05639998)
- Testing
- COVAXIN(BBV152), BBV154 Intranasal Vaccine
- Where
- 11 sites in India
- Volunteers
- 608 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
COVID-19
Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada
This study is a phase I /II adaptive clinical trial to evaluate the safety, tolerability and the Immunogenicity of Ad5-nCoV in healthy adults from 18 to <55 and 65 to <85 years of age，with the randomized, observer-blind…
- Trial name
- NCT04398147
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- Canada
- Volunteers
- 696 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
COVID-19
Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults
A randomized, observer-blind, placebo-controlled immuno-bridging, and broadening study to demonstrate the equivalence of the immune response between participants enrolled in Phase 3 efficacy trial in India and demographically…
- Trial name
- NCT05258669
- Testing
- BBV152
- Where
- 10 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Ocugen
Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19)
A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir
Healthy adults will be enrolled into this open-label, Phase 1 research study. Participants will spend about 9 nights and 10 days in the clinical research unit (CRU) and the total time in the study will be about 11 weeks.
- Conditions
- Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19), COVID-19 (Coronavirus Disease 2019), Upper Respiratory Tract Infections
- Trial name
- NCT07552779
- Testing
- Ibuzatrelvir co-process API film coated tablet, Ibuzatrelvir filmcoated tablet
- Where
- Belgium
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS-CoV-2
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
The primary goal for this study is to evaluate the safety and reactogenicity of 3 dose levels of mRNA-1283 and 1 dose level of mRNA-1273 vaccine given to healthy adults in 2 doses, 28 days apart, and 1 dose level of mRNA-1283…
- Trial name
- NCT04813796
- Testing
- mRNA-1283, mRNA-1273
- Where
- 5 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Sars-CoV-2 Infection, COVID-19
COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability
SARS-CoV-2 rapid antigen over the counter usability study.
- Trial name
- NCT05584189
- Testing
- Rapid SARS-CoV-2 Antigen Test
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- MP Biomedicals, LLC
SARS-CoV-2 Infection
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity and safety profile.
- Trial name
- NCT04636697
- Testing
- Intramuscular injection, Intramuscular vaccine
- Where
- 91 sites in United States, Argentina and 4 more
- Volunteers
- 30,918 people, healthy volunteers welcome
- Sponsor
- Medicago
Covid19, SARS-COV-2 Infection
A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2
To evaluate the prevention of SARS-COV-2 infection after administration of DWJ1248 in person who contact from COVID-19 confirmed patient compared to the placebo.
- Trial name
- NCT04721535
- Testing
- DWJ1248
- Where
- South Korea
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
COVID-19, Infection Viral
A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers
An open label, dose escalation, and dose expansion study to evaluate the safety, reactogenicity and immunogenicity of two SARS-CoV-2 DNA plasmid vaccine candidates, VB10.2129 (C1) and VB10.2210 (C2).
- Conditions
- COVID-19, Infection Viral, Infections
- Trial name
- NCT05069623
- Testing
- VB10.2129, VB10.2210
- Where
- 2 sites in Norway
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Nykode Therapeutics ASA
COVID-19 Vaccine, COVID-19
Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19
The investigational product Baiya SARS-CoV-2 Vax 2 vaccine is a second-generation of protein subunit vaccine from plant to prevent COVID-19 disease.
- Trial name
- NCT05873374
- Testing
- 50 μg Baiya SARS-CoV-2 Vax 2
- Where
- Thailand
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Baiya Phytopharm Co., Ltd.
Covid-19
Exploratory Study to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers
The aim of this study is to explore potential for reduction of incidence and/or morbidity of SARS-CoV-2 infection in healthcare personnel. The study will include a comparison between placebo and RUTI® vaccine in a 2:1 design.
- Trial name
- NCT04903184
- Testing
- RUTI® vaccine
- Where
- 6 sites in Argentina
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- RUTI Immunotherapeutics S.L.
COVID-19 Vaccines
The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)
This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind study designed to evaluate the safety, immunogenicity and efficacy of ARCT-154 in adult participants to be enrolled in Vietnam.
- Trial name
- ARCT-154-01 (NCT05012943)
- Testing
- ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine, Astra Zeneca COVID-19 vaccine
- Where
- 3 sites in Vietnam
- Volunteers
- 19,474 people, healthy volunteers welcome
- Sponsor
- Vinbiocare Biotechnology Joint Stock Company
COVID-19
A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅱ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults ⩾18 years.
- Trial name
- NCT04756323
- Testing
- medium dosage inactivated SARS-CoV-2 vaccine, high dosage inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd